Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 138.76M P/E - EPS this Y -58.60% Ern Qtrly Grth -
Income -38.77M Forward P/E -5.37 EPS next Y -4.30% 50D Avg Chg -2.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 2.00%
Dividend N/A Price/Book 1.36 EPS next 5Y - 52W High Chg -51.00%
Recommedations 1.70 Quick Ratio 10.29 Shares Outstanding 72.59M 52W Low Chg 62.00%
Insider Own 1.25% ROA -30.88% Shares Float 43.50M Beta 0.97
Inst Own 77.21% ROE -48.09% Shares Shorted/Prior 1.39M/1.50M Price 2.31
Gross Margin - Profit Margin - Avg. Volume 388,483 Target Price 9.11
Oper. Margin - Earnings Date Nov 7 Volume 52,422 Change -6.48%
About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Trevi Therapeutics, Inc. News
07:30 AM Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
11/07/24 Q3 2024 Trevi Therapeutics Inc Earnings Call
11/07/24 Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ...
11/06/24 Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
10/30/24 Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024
10/23/24 Rosalind Advisors, Inc. Reduces Stake in Trevi Therapeutics Inc.
06:30 AM Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
10/15/24 Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
10/09/24 Trevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges ...
10/03/24 Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
09/30/24 Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer
09/26/24 Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024
09/04/24 Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024
08/30/24 Abercrombie upgraded, Dollar General downgraded: Wall Street's top analyst calls
08/28/24 Trevi Therapeutics to Participate in September Investor and Medical Conferences
08/08/24 Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance
08/07/24 Institutional investors in Trevi Therapeutics, Inc. (NASDAQ:TRVI) see US$40m decrease in market cap last week, although long-term gains have benefitted them.
08/01/24 Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024
07/02/24 Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events
06/27/24 Here's Why We're Not Too Worried About Trevi Therapeutics' (NASDAQ:TRVI) Cash Burn Situation
TRVI Chatroom

User Image Uhhfdt Posted - 1 day ago

$TRVI going under 1.00 down every day.

User Image abcdzepeda Posted - 6 days ago

$TRVI i’ve been following this ticker for months and researching the pipeline, and I decided to jump in because it looks very promising. I’ve learned to look and research the team that is leading a company before making a decision to invest. One of the board members here at Trevi is a man by the name of David Meeker, he is the CEO of rhythm pharmaceuticals, which is a company that is doing amazing. Work with rare obesity. I invested in rhythm pharmaceuticals before the FDA approved their medication back in 2020 at that time it was trading for $3.49 today it is just under $60 a share. I guess what I’m trying to say is that I believe the exact same thing is going to happen to Trevi and this is the perfect time to get as many shares as possible, because they have an awesome team JMO!

User Image Trx921 Posted - 1 week ago

$TRVI crickets..

User Image Trx921 Posted - 2 weeks ago

@Kingjake26 thoughts on $TRVI ?

User Image KingNeptune Posted - 2 weeks ago

$BOLD $TRVI $VTGN $NRBO are my $3 stocks I'm liking for positive movement through the end of the year. I'd add $SLS but it's not there yet. Very possible it'll be in the 3s by the EOY. What's everyone else thinking? About these or other $3 darlings?

User Image KingNeptune Posted - 10/22/24

$TRVI Did I just see that this has a $21 Price Target with EF Hutton? Wow! I knew this was a gem, but dang! May have to add a few more in the morning. Up 20% in the past month already!

User Image vu_jade Posted - 1 month ago

$TRVI ⛲️

User Image canadian_trader Posted - 1 month ago

$TRVI Upcoming Commercial and Investor Conferences https://ir.trevitherapeutics.com/2024-10-15-Trevi-Therapeutics-to-Participate-in-Upcoming-Commercial-and-Investor-Conferences

User Image Thestocktraderhubzee Posted - 1 month ago

WATCHLIST OCT 07 2024.. $CVE BMO Capital Maintains Outperform on Cenovus Energy, Lowers Price Target to $31 $BTG Jefferies Maintains Buy on B2Gold, Raises Price Target to $5 $EQT BMO Capital Maintains Outperform on EQT, Raises Price Target to $40 $ORI Piper Sandler Maintains Overweight on Old Republic Intl, Raises Price Target to $36 $TRVI EF Hutton Maintains Buy on Trevi Therapeutics, Maintains $21 Price Target

User Image StreetwiseReports Posted - 1 month ago

CT Biotech Ready for Clinical Milestones: https://ow.ly/2FIF50TEBgo Trevi Therapeutics Inc. has made progress in its clinical trials for Haduvio, particularly in treating chronic cough in idiopathic pulmonary fibrosis patients and refractory chronic cough, according to an EF Hutton research note. $TRVI #biotechstocks

User Image Thestocktraderhubzee Posted - 1 month ago

$TRVI Needham Reiterates Buy on Trevi Therapeutics, Maintains $8 Price Target

User Image DonCorleone77 Posted - 1 month ago

$PEV $TRVI $IRIX $WULF $RARE Please feel free to follow me for pre-market and after hours movers every day. AFTER-HOURS MOVERS: Currently Higher After Earnings: -- Phoenix Motor (PEV) up 192.8% Currently Also Higher: -- Trevi Therapeutics (TRVI) up 3.6% after update on Haduvio clinical development program -- Iridex (IRIX) up 1.7% after naming new CEO -- Ultragenyx Pharmaceutical (RARE) up 0.6% after update on Cyprus2+ study, to submit protocol amendment Currently Lower: -- TeraWulf (WULF) down 3.4% after announcing monetization of equity interests in Nautilus JV

User Image themacromindset Posted - 1 month ago

$TRVI $TRVI Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer

User Image KingNeptune Posted - 09/30/24

$TRVI Been sleepy and coming alive. Love it.

User Image Doozio Posted - 09/29/24

$trvi MAMA always said it’s comes in 3s n da FUTUre of 🧠⏰ is gonna be $mrvi lous NOW during 🧠⏰♾️

User Image vu_jade Posted - 09/27/24

$TRVI more coins in the fountain

User Image Himel92 Posted - 09/27/24

The Last month Performance for $TRVI Opening Price: $2.91 Closing Price: $3.15 Highest Price: $3.69 Lowest Price: $2.83 Percentage Change: 8.25% Data analyst: AITX

User Image YouVSYou Posted - 09/26/24

$eose 💫 20MA support on daily Double Inside day $2.50/2.69/3/3.20 $xcur WwW over $4.05 Currently in a Bear pennant Needs to clear $lunr still in a wedge on the 2/4 hour Dog fight 8.11, may take some time for the setup $GLMD Golden cross on daily Tracking this double bottom $TRVI 50MA support reclaim on daily Hammer candle demand zone 2.95

User Image Stocksrunner Posted - 09/26/24

Thursday's Epic Comebacks! 💥These stocks hit rock bottom during the session but came back STRONGER by the close! Big props to $BDTX, $FUL, $VINE, $CORZ, and $TRVI for bouncing back big time! 🚀 What a recovery to wrap up Thursday!

User Image DaStonksOnlyGoUpRight Posted - 09/26/24

$TRVI

User Image DonCorleone77 Posted - 09/26/24

$TRVI Trevi Therapeutics' Haduvio shows cough relief efficacy in Phase 2a trial Trevi Therapeutics, developing investigational therapy Haduvio - oral nalbuphine - for the treatment of chronic cough in idiopathic pulmonary fibrosis - IPF - and refractory chronic cough - RCC -, announced that data from the Phase 2a CANAL trial will be presented at CHEST 2024 held in Boston from October 6-9. The presentation will include cough data from 38 IPF patients who completed at least 1 treatment period of the CANAL trial. Results demonstrated a significant increase in relief-of-cough time, reduced cough time, and reduced cough intensity in IPF patients with nalbuphine ER compared with placebo. The safety results of the trial were generally consistent with the known safety profile of nalbuphine ER from previous trials. The most frequently reported treatment-emergent adverse events with nalbuphine ER treatment were nausea, dizziness, anxiety, constipation, vomiting, dry mouth, headache, somnolence, dyspnea, decreased appetite, fatigue and lethargy.

User Image Stock_Titan Posted - 09/26/24

$TRVI Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024 https://www.stocktitan.net/news/TRVI/trevi-therapeutics-announces-additional-analyses-of-cough-relief-z7uwb30vn5k5.html

User Image JoshThe3rd Posted - 09/24/24

$TRVI DD time

User Image DaStonksOnlyGoUpRight Posted - 09/24/24

$TRVI Bad idea. This one is going back down to the $2 range where it belongs.

User Image m97531 Posted - 09/22/24

$TRVI Any technical analysts can read the chart for amateurs ? Thx

User Image Doozio Posted - 2 months ago

$MRVI $TRVI 🧠⏰♾️ to PEGA da greed

User Image vu_jade Posted - 2 months ago

$TRVI okay I’ll throw a couple of coins here 🪙 🪙

User Image Shlobby Posted - 2 months ago

$TRVI the monthly is the $scsc, the weekly is the 🧠 and the daily is $afrm ation

User Image Doozio Posted - 2 months ago

@Shlobby so $trvi n $mrvi scrabbled NOW in 🧠⏰♾️?

User Image Doozio Posted - 2 months ago

$TRVI wen 🧠⏰?

Analyst Ratings
EF Hutton Buy Sep 17, 24
HC Wainwright & Co. Buy Aug 30, 24
Raymond James Outperform Aug 30, 24
EF Hutton Buy Aug 19, 24
Rodman & Renshaw Buy Jun 13, 24
Needham Buy May 8, 24
Needham Buy Apr 9, 24
Oppenheimer Outperform Mar 21, 24
Needham Buy Mar 21, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Delfini Lisa Chief Financial Offi.. Chief Financial Officer Apr 11 Sell 1.84 840 1,546 26,189 04/12/23
Delfini Lisa Chief Financial Offi.. Chief Financial Officer Apr 11 Option 0.51 2,292 1,169 27,029 04/12/23
TPG GP A, LLC 10% Owner 10% Owner Apr 28 Sell 2.76 23,434 64,678 4,801,449 05/02/22
Walker Paul Edward 10% Owner 10% Owner Apr 11 Buy 1.9 3,580,526 6,802,999 948,948 04/13/22
Sonsini Peter W. 10% Owner 10% Owner Apr 11 Buy 1.9 3,580,526 6,802,999 948,948 04/13/22
SANDELL SCOTT D 10% Owner 10% Owner Apr 11 Buy 1.9 3,580,526 6,802,999 948,948 04/13/22
Makhzoumi Mohamad 10% Owner 10% Owner Apr 11 Buy 1.9 3,580,526 6,802,999 948,948 04/13/22
Florence Anthony A. Jr. 10% Owner 10% Owner Apr 11 Buy 1.9 3,580,526 6,802,999 948,948 04/13/22
Chang Carmen 10% Owner 10% Owner Apr 11 Buy 1.9 3,580,526 6,802,999 948,948 04/13/22
Behbahani Ali 10% Owner 10% Owner Apr 11 Buy 1.9 3,580,526 6,802,999 948,948 04/13/22
BASKETT FOREST 10% Owner 10% Owner Apr 11 Buy 1.90 2,631,578 4,999,998 10,421,428 04/13/22
New Enterprise Associates 16,... 10% Owner 10% Owner Apr 11 Buy 1.90 2,631,578 4,999,998 10,421,428 04/13/22